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Review question
What is the best available evidence 
on the safety and efficacy of using 
human albumin for the treatment of 
intra-dialytic hypotension (IDH) in 
haemodialysis patients?
Relevance for clinical practice
Hypotension is the most common 
intra-dialytic complication occurring in 
20%–50% of the haemodialysis sessions 
(Irwin & Rippe, 2003). Despite the use 
of a variety of preventative measures, 
such as sodium profiling, sequential 
ultrafiltration and prescription dialysate, 
some patients still experience the adverse 
effects of a sudden drop in blood pressure 
(BP). The main cause of this unpleasant 
complication is fluid removal during 
the dialysis procedure, although other 
factors are also known to contribute, 
for example the components of the 
dialysis procedure and other patient-
specific factors such as left ventricular 
dysfunction.
The primary mode of treatment is to 
replace fluids as a means of increasing 
the circulating blood volume. While 
fluid replacement can have favourable 
short-term results in correcting the 
hypotension and relieving the symptoms, 
the long-term effects can cause more 
serious complications such as cardiac 
or cerebral ischaemia. Several fluids can 
be used for this purpose such as saline, 
human albumin, gelatin or starches. The 
use of albumin as a replacement fluid 
is controversial, mainly due to the cost 
implications as well as the potential for 
transmission of blood-borne viral disease 
such as Creutzfeldt-Jacob Disease (CJD).
Nurses need to be aware of the benefits 
and risks associated with the fluids 
they are using for treatment to enable 
them to make informed choices when 
selecting a fluid for the correction of 
IDH. This is especially true where there 
is an increased potential for hypotension 
during haemodialysis associated with 
increasing age and comorbid conditions 
of future dialysis patients.
This review was performed to determine 
if albumin provides a therapeutic 
advantage over other fluids in the 
treatment of hypotension during dialysis.
Characteristics of the evidence
The search focused on randomised, 
controlled trials (RCTs), quasi-RCTs 
and randomised, crossover studies 
investigating the use of human albumin, 
alone or in combination with other fluids 
for treatment of IDH in maintenance 
haemodialysis patients. There was a 
requirement that all participants be adults 
undergoing long-term haemodialysis and 
experiencing episodes of systematic IDH. 
IDH was defined as a decrease in systolic 
BP of at least 10 mmHg or a systolic BP 
less than 100 mmHg with symptoms 
such as cramps, nausea, vomiting and 
dizziness.
One study met the inclusion criteria for 
the review, which compared albumin 
to normal saline; no other trials were 
identified that compared albumin with 
any other fluid. Adults who received 
haemodialysis treatments for a minimum 
period of three months and who had 
experienced at least three episodes of 
IDH in the 60-day period leading up to 
enrolment into the study were included. 
Patients were excluded if they were 
known to have sensitivity to albumin.
This was a well-conducted trial involving 
45 patients arranged into evenly balanced 
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groups, randomised to two treatment 
sequences. Sequence one patients 
received 5% albumin to treat the first 
episode of IDH, with the second and 
third episodes of IDH treated with 
normal saline. Patients in sequence two 
received normal saline to treat the first 
episode of IDH, with the second and 
third episodes of IDH treated with 5% 
albumin.
The primary outcome measure was the 
percentage of the target ultrafiltration 
achieved. The secondary outcome 
measures were post-dialysis systolic and 
diastolic BP, volume of study fluid used, 
time to restore BP and total nursing 
time to treat hypotensive episodes. The 
results of this trial showed no significant 
difference between albumin and saline 
in the percentage of target ultrafiltration 
achieved.
In summary, the study showed that 
5% albumin is not superior to normal 
saline for the treatment of symptomatic 
hypotension in maintenance 
haemodialysis patients with a history of 
IDH.
Implications for clinical practice
There is insufficient evidence to support 
the therapeutic advantage that albumin 
has over crystalloids or non-protein 
colloids for the treatment of symptomatic 
hypotension during haemodialysis
The evidence suggests that there is no 
significant clinical benefit of using 5% 
albumin over normal saline; therefore, 
saline should be the first-line treatment 
of IDH in stable dialysis patients.
Implications for research
Further studies are required comparing 
albumin to crystalloids or non-protein 
crystalloids for the prophylactic 
maintenance of blood value and BP 
during haemodialysis for patients at risk 
of hypotension.
There is a need to compare the 
efficiency of non-protein colloids such 
as pentastarch versus albumin for the 
treatment of IDH.
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On behalf of the Victorian Organising 
Committee we invite you to join us in Melbourne 
for the 40th Annual Renal Society of Australasia 
Conference in June 2012.
Melbourne boasts great events, a passion for food and wine and 
a fabulous arts scene. Known as a style-setter, Melbourne is home 
to a non-stop program of festivals, renowned dining, major art 
exhibitions and musical extravaganzas and is known as the cultural 
capital of Australia.
The theme for the conference,  Celebrating our Culture and Diversity 
in Renal Care offers an opportunity to bring together novices, 
practitioners, researchers and experts to share knowledge, innovation, 
experience and expertise.
The conference will be held at The Sebel Albert Park Melbourne. 
This venue is centrally located on Queens Road, minutes from 
Melbourne’s central business district and St Kilda Road. The hotel 
overlooks picturesque Albert Park Lake. So come along and help us 
celebrate the RSA’s 40th birthday party.
We encourage everybody to take up the challenge and submit an 
abstract and share the rewarding experience of participating at the 
conference. We look forward to seeing you in Melbourne in 2012.
Jenny Beavis
Convenor RSA 2012
WHO SHOULD ATTEND?
• Nurses 
• Transplant coordinators 
• Pharmacists 
• Dieticians 
• Social Workers 
• Educators 
• Technicians 
• Researchers 
•  Healthcare professionals 
working with people who 
have kidney disease
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